TDMS Study 05069-08 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE
NTP Experiment-Test: 05069-08 Report: PEIRPT05
Study Type: CHRONIC Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
CORE STUDY (REV.1)
Facility: TSI Mason Research
Chemical CAS #: 147-47-7
Lock Date: 08/21/92
Cage Range: All
Reasons For Removal: 25019 Moribund Sacrifice 25020 Natural Death
25026 Other 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 19 10 9 9
Natural Death 12 19 19 19
Survivors
Terminal Sacrifice 19 21 22 22
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (49) (47) (48) (47)
Intestine Large, Rectum (49) (47) (47) (46)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Intestine Small, Jejunum (49) (41) (44) (44)
Carcinoma 1 (2%)
Intestine Small, Ileum (45) (40) (42) (40)
Liver (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocellular Adenoma 2 (4%)
Sarcoma, Metastatic, Spleen 1 (2%)
Mesentery (8) (8) (4) (3)
Carcinoma, Metastatic, Uncertain Primary Site 1 (13%)
Schwannoma Malignant, Metastatic, Uterus 1 (25%)
Oral Mucosa (1) (1)
Squamous Cell Carcinoma 1 (100%)
Pharyngeal, Squamous Cell Papilloma 1 (100%)
Pancreas (50) (50) (50) (50)
Sarcoma, Metastatic, Spleen 1 (2%)
Salivary Glands (50) (50) (50) (50)
Schwannoma Malignant, Metastatic, Harderian
Gland 1 (2%)
Stomach, Forestomach (50) (50) (49) (50)
Stomach, Glandular (50) (50) (50) (49)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 3 (6%) 1 (2%) 1 (2%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (49) (50) (50) (50)
Carcinoma 1 (2%)
Pars Distalis, Adenoma 30 (61%) 28 (56%) 31 (62%) 33 (66%)
Pars Distalis, Carcinoma 2 (4%) 2 (4%) 1 (2%)
Thyroid Gland (49) (50) (48) (49)
C-Cell, Adenoma 7 (14%) 5 (10%) 2 (4%) 2 (4%)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (49) (46) (45) (49)
Adenoma 4 (8%) 2 (4%) 5 (11%) 2 (4%)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Ovary (50) (50) (50) (50)
Uterus (50) (50) (50) (50)
Polyp Stromal 4 (8%) 3 (6%) 4 (8%)
Sarcoma Stromal 1 (2%) 1 (2%)
Schwannoma Malignant 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Vagina (1) (2)
Sarcoma Stromal, Metastatic, Uterus 1 (100%)
Schwannoma Malignant, Metastatic, Uterus 1 (50%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50) (50)
Lymph Node (13) (10) (7) (1)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (14%)
Mediastinal, Sarcoma, Metastatic, Spleen 1 (14%)
Page 3
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mandibular (50) (50) (50) (50)
Schwannoma Malignant, Metastatic, Harderian
Gland 1 (2%)
Lymph Node, Mesenteric (50) (49) (50) (50)
Spleen (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Sarcoma 1 (2%)
Thymus (47) (50) (49) (50)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (48) (49) (49) (50)
Adenoma 1 (2%) 1 (2%)
Adenoma, Multiple 1 (2%)
Carcinoma 3 (6%) 5 (10%) 2 (4%)
Carcinoma, Multiple 1 (2%)
Fibroadenoma 18 (38%) 10 (20%) 12 (24%) 15 (30%)
Fibroadenoma, Multiple 7 (15%) 6 (12%) 3 (6%) 1 (2%)
Skin (50) (50) (50) (50)
Fibroma 1 (2%)
Melanoma Benign 1 (2%)
Squamous Cell Papilloma 1 (2%)
Pinna, Melanoma Malignant 1 (2%)
Skin, Site of Application, Keratoacanthoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Skeletal Muscle (1)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Malignant 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 2 (4%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Sarcoma, Metastatic, Spleen 1 (2%)
Nose (50) (50) (50) (49)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Oral
Mucosa 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1)
Nerve, Schwannoma Malignant 1 (100%)
Zymbal's Gland (1) (1) (1)
Carcinoma 1 (100%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
Urinary Bladder (50) (48) (49) (50)
Transitional Epithelium, Carcinoma 1 (2%)
Transitional Epithelium, Papilloma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Leukemia Granulocytic 1 (2%)
Leukemia Mononuclear 22 (44%) 16 (32%) 23 (46%) 10 (20%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 43 47 43
Total Primary Neoplasms 117 90 94 80
Total Animals with Benign Neoplasms 43 37 37 38
Total Benign Neoplasms 81 62 62 59
Total Animals with Malignant Neoplasms 29 26 28 18
Total Malignant Neoplasms 36 28 32 21
Total Animals with Metastatic Neoplasms 5 3 6 1
Total Metastatic Neoplasm 6 4 13 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Natural Death 21 26 25 23
Moribund Sacrifice 24 22 20 26
Survivors
Terminal Sacrifice 5 2 4 1
Other 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (47) (47) (42) (44)
Fibroma 1 (2%)
Intestine Large, Rectum (47) (49) (49) (45)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Intestine Large, Cecum (42) (44) (36) (39)
Intestine Small, Duodenum (50) (50) (46) (48)
Intestine Small, Jejunum (46) (45) (42) (39)
Intestine Small, Ileum (40) (37) (34) (37)
Fibrosarcoma 1 (3%)
Liver (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Bone 1 (2%)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Hepatocellular Carcinoma 1 (2%) 2 (4%) 1 (2%)
Hepatocellular Adenoma 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mesentery (10) (3) (3) (4)
Oral Mucosa (1)
Squamous Cell Carcinoma 1 (100%)
Pancreas (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Mixed Tumor Benign 1 (2%)
Salivary Glands (49) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (49)
Stomach, Glandular (50) (50) (50) (49)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (1) (1)
Aorta, Osteosarcoma, Metastatic, Bone 1 (100%)
Heart (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Bone 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Bone 1 (2%)
Pheochromocytoma Malignant 2 (4%)
Pheochromocytoma Benign 2 (4%) 7 (14%) 5 (10%) 2 (4%)
Bilateral, Pheochromocytoma Benign 3 (6%) 1 (2%)
Islets, Pancreatic (50) (50) (49) (50)
Adenoma 6 (12%) 2 (4%) 3 (6%)
Carcinoma 1 (2%) 1 (2%)
Parathyroid Gland (48) (49) (46) (49)
Adenoma 1 (2%)
Pituitary Gland (49) (50) (50) (49)
Pars Distalis, Adenoma 25 (51%) 23 (46%) 18 (36%) 18 (37%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (50) (50) (50) (50)
C-Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Preputial Gland (50) (49) (49) (49)
Adenoma 1 (2%) 2 (4%) 3 (6%) 1 (2%)
Carcinoma 1 (2%) 1 (2%) 2 (4%)
Prostate (50) (50) (50) (49)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Page 8
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Seminal Vesicle (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Testes (50) (50) (50) (50)
Bilateral, Interstitial Cell, Adenoma 18 (36%) 32 (64%) 24 (48%) 27 (54%)
Interstitial Cell, Adenoma 18 (36%) 9 (18%) 13 (26%) 14 (28%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Lymph Node (19) (15) (6) (9)
Lymph Node, Mandibular (49) (50) (50) (50)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Lymph Node, Mesenteric (50) (50) (50) (49)
Spleen (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Lipoma 1 (2%)
Thymus (45) (44) (49) (46)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (42) (42) (45) (40)
Adenoma 2 (4%)
Fibroadenoma 1 (2%) 1 (3%)
Skin (50) (50) (49) (50)
Basal Cell Adenoma 1 (2%)
Keratoacanthoma 1 (2%) 1 (2%) 1 (2%)
Squamous Cell Papilloma 1 (2%) 2 (4%) 1 (2%)
Pinna, Melanoma Malignant 1 (2%)
Pinna, Squamous Cell Papilloma 1 (2%) 1 (2%) 2 (4%)
Sebaceous Gland, Skin, Site of Application,
Adenoma 1 (2%)
Skin, Site of Application, Keratoacanthoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma, Multiple 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Fibroma 1 (2%)
Subcutaneous Tissue, Skin, Site of
Page 9
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Application, Fibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Osteosarcoma 1 (2%) 1 (2%)
Turbinate, Chondroma 1 (2%)
Vertebra, Fibrosarcoma 1 (2%)
Skeletal Muscle (1) (2) (1)
Fibrosarcoma, Metastatic, Bone 1 (100%)
Fibrous Histiocytoma 1 (100%)
Osteosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Malignant 1 (2%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Fibrous Histiocytoma, Metastatic, Skeletal
Muscle 1 (2%)
Melanoma Malignant, Metastatic, Skin 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Osteosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Nose (50) (49) (50) (50)
Osteosarcoma, Metastatic, Bone 1 (2%)
Glands, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (3) (1) (2) (2)
Carcinoma, Metastatic, Zymbal's Gland 1 (100%)
Zymbal's Gland (1) (1) (1)
Carcinoma 1 (100%) 1 (100%) 1 (100%)
Page 10
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%) 7 (14%) 8 (16%) 7 (14%)
Renal Tubule, Adenoma, Multiple 2 (4%)
Renal Tubule, Adenoma, Oncocytic 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (49) (50) (50) (48)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Leukemia Mononuclear 25 (50%) 25 (50%) 17 (34%) 14 (28%)
Mesothelioma Malignant 1 (2%) 4 (8%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05069-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 05/23/95
Route: DERMAL,SOLUTION Time: 17:13:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 36 MG/KG 60 MG/KG 100
MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 48 50 46 49
Total Primary Neoplasms 109 134 114 105
Total Animals with Benign Neoplasms 48 50 45 47
Total Benign Neoplasms 80 95 87 80
Total Animals with Malignant Neoplasms 27 34 23 21
Total Malignant Neoplasms 29 39 27 25
Total Animals with Metastatic Neoplasms 1 7 6 2
Total Metastatic Neoplasm 1 30 16 14
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------